- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05921994
중등도에서 중증 화농땀샘염 성인 환자의 secukinumAb 치료 패턴에 대한 실제 인구 데이터를 수집하기 위한 장기 관찰, 전향적, 다기관 연구. (ANIMA)
중등도에서 중증 화농땀샘염(HS) 성인 환자의 secukinumAb 치료 패턴에 대한 실제 인구 데이터를 수집하기 위한 장기 관찰, 전향적, 다기관 연구(ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
연구 개요
상세 설명
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Aachen, 독일, 52064
- Novartis Investigative Site
-
Ahaus, 독일, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, 독일, 09456
- Novartis Investigative Site
-
Bad Steben, 독일, 95138
- Novartis Investigative Site
-
Baden-Baden, 독일, 76530
- Novartis Investigative Site
-
Berlin, 독일, 12159
- Novartis Investigative Site
-
Berlin, 독일, 13595
- Novartis Investigative Site
-
Bielefeld, 독일, 33647
- Novartis Investigative Site
-
Bochum, 독일, 44791
- Novartis Investigative Site
-
Bonn, 독일, 53105
- Novartis Investigative Site
-
Brandenburg, 독일, 14776
- Novartis Investigative Site
-
Bremen, 독일, 28359
- Novartis Investigative Site
-
Buxtehude, 독일, 21614
- Novartis Investigative Site
-
Bückeburg, 독일, 31675
- Novartis Investigative Site
-
Chemnitz, 독일, 09117
- Novartis Investigative Site
-
Chemnitz, 독일, 09113
- Novartis Investigative Site
-
Cologne, 독일, 51065
- Novartis Investigative Site
-
Delitzsch, 독일, 04509
- Novartis Investigative Site
-
Dessau, 독일, 06847
- Novartis Investigative Site
-
Dorsten, 독일, 46282
- Novartis Investigative Site
-
Dortmund, 독일, 44137
- Novartis Investigative Site
-
Dresden, 독일, 01309
- Novartis Investigative Site
-
Düren, 독일, 52349
- Novartis Investigative Site
-
Emsdetten, 독일, 48282
- Novartis Investigative Site
-
Erlangen, 독일, 91054
- Novartis Investigative Site
-
Falkenberg, 독일, 04895
- Novartis Investigative Site
-
Falkensee, 독일, 14612
- Novartis Investigative Site
-
Freising, 독일, 85354
- Novartis Investigative Site
-
Geilenkirchen, 독일, 52511
- Novartis Investigative Site
-
Gera, 독일, 07548
- Novartis Investigative Site
-
Gernsbach, 독일, 76593
- Novartis Investigative Site
-
Gladbeck, 독일, 45964
- Novartis Investigative Site
-
Großenhain, 독일, 01558
- Novartis Investigative Site
-
Hamburg, 독일, 20246
- Novartis Investigative Site
-
Hamburg, 독일, 22143
- Novartis Investigative Site
-
Hanover, 독일, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, 독일, 77716
- Novartis Investigative Site
-
Hofgeismar, 독일, 34369
- Novartis Investigative Site
-
Jena, 독일, 07743
- Novartis Investigative Site
-
Jülich, 독일, 52428
- Novartis Investigative Site
-
Karlsruhe, 독일, 76133
- Novartis Investigative Site
-
Kempen, 독일, 47906
- Novartis Investigative Site
-
Lübeck, 독일, 23538
- Novartis Investigative Site
-
Magdeburg, 독일, 39120
- Novartis Investigative Site
-
Magdeburg, 독일, 39104
- Novartis Investigative Site
-
Mainz, 독일, 55116
- Novartis Investigative Site
-
Marburg, 독일, 35043
- Novartis Investigative Site
-
Minden, 독일, 32429
- Novartis Investigative Site
-
Mönchengladbach, 독일, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, 독일, 21629
- Novartis Investigative Site
-
Nuremberg, 독일, 90419
- Novartis Investigative Site
-
Oberasbach, 독일, 90522
- Novartis Investigative Site
-
Oelde, 독일, 59302
- Novartis Investigative Site
-
Peitz, 독일, 03185
- Novartis Investigative Site
-
Potsdam, 독일, 14469
- Novartis Investigative Site
-
Remscheid, 독일, 42897
- Novartis Investigative Site
-
Selters, 독일, 56242
- Novartis Investigative Site
-
Simmern, 독일, 55469
- Novartis Investigative Site
-
Soest, 독일, 59494
- Novartis Investigative Site
-
Stolberg, 독일, 52222
- Novartis Investigative Site
-
Unna, 독일, 59423
- Novartis Investigative Site
-
Wittlich, 독일, 54316
- Novartis Investigative Site
-
Wuppertal, 독일, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, 독일, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, 독일, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, 독일, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, 독일, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, 독일, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, 독일, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, 독일, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, 독일, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, 독일, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, 독일, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, 독일, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, 독일, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, 독일, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, 독일, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, 독일, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, 독일, 06886
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
설명
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients receiving up-titration
기간: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
기간: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
기간: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
기간: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
기간: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
기간: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
기간: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
기간: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
기간: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
기간: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
기간: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
기간: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .